Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
KardiganKARD +2.97%11 FCF Yield % is -8.63 as of Aug. 04, 2026. GuruFocus rates KARD with a GF Score™ of 11/100. The stock has 1 warning sign investors should review. Among 1,410 Biotechnology companies, Kardigan ranks better than 52.34% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
As of today, Kardigan's Trailing 12-Month Free Cash Flow is $-157.70 Mil, and Market Cap is $1,827.88 Mil. Therefore, Kardigan's FCF Yield % for today is -8.63%.
The historical rank and industry rank for Kardigan's FCF Yield % or its related term are showing as below:
KARD'
s FCF Yield % Range Over the Past 10 Years
Min: -8.91 Med: 0 Max: 0
Current: -8.63
KARD's FCF Yield % is ranked better than 52.34% of 1410
companies
in the Biotechnology industry
Industry Median: -9.91
vs KARD: -8.63
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Kardigan FCF Yield % Related Terms
Kardigan FCF Yield % Historical Data
* Premium members only.
The historical data trend for Kardigan's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kardigan FCF Yield % Chart
Kardigan Annual Data
Trend
Dec24
Dec25
FCF Yield %
0.00
0.00
Kardigan Semi-Annual Data
Dec24
Dec25
FCF Yield %
0.00
0.00
KARD vs OCUL, GHRS, FTRE: FCF Yield % Comparison
For the Biotechnology subindustry, Kardigan's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kardigan FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kardigan's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Kardigan's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kardigan (KARD) has a FCF Yield % of -8.63 as of Aug. 04, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Kardigan and its competitors. According to the industry distribution chart, Kardigan ranks #672 out of 1410 companies in the Biotechnology industry, placing it in the top 47.7%.
Is Kardigan's FCF Yield % too high?
Kardigan's current FCF Yield % is -8.63. Based on the distribution chart, Kardigan ranks #672 out of 1410 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Kardigan has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Kardigan's FCF Yield % compare to OCUL and GHRS?
According to the Biotechnology industry distribution chart, Kardigan ranks #672 out of 1410 companies for FCF Yield %. This puts Kardigan in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Kardigan and its competitors. Kardigan's current FCF Yield % is -8.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kardigan stock overvalued right now?
Kardigan (KARD) has a current FCF Yield % of -8.63. The current FCF Yield % is -8.63. Kardigan's overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Kardigan (KARD), the current FCF Yield % is -8.63 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kardigan Inc is a clinical-stage therapeutics company focused on developing medicines for cardiovascular diseases. Its activities include the research and development of targeted therapies for cardiovascular conditions for which no approved treatments currently exist. The company's clinical-stage programs include Danicamtiv, Ataciguat, and Tonlamarsen, which are being developed for cardiovascular disease indications. The company operates and manages its business as a single operating and reportable segment, focused on the discovery and development of novel therapeutic products to treat cardiovascular disease.
11GF Score
Get the complete analysis for KARD
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KARD has been successfully added to your 
